262 related articles for article (PubMed ID: 34626200)
21. OnabotulinumtoxinA 100 U significantly improves all idiopathic overactive bladder symptoms and quality of life in patients with overactive bladder and urinary incontinence: a randomised, double-blind, placebo-controlled trial.
Chapple C; Sievert KD; MacDiarmid S; Khullar V; Radziszewski P; Nardo C; Thompson C; Zhou J; Haag-Molkenteller C
Eur Urol; 2013 Aug; 64(2):249-56. PubMed ID: 23608668
[TBL] [Abstract][Full Text] [Related]
22. Relationships between improvements in symptoms and patient assessments of bladder condition, symptom bother and health-related quality of life in patients with overactive bladder treated with tolterodine.
Coyne KS; Elinoff V; Gordon DA; Deng DY; Brodsky M; Glasser DB; Jumadilova Z; Carlsson M
Int J Clin Pract; 2008 Jun; 62(6):925-31. PubMed ID: 18479285
[TBL] [Abstract][Full Text] [Related]
23. Reliability of the Polish version of the Overactive Bladder Symptom Score (OABSS) questionnaire : Correlation of the OABSS with urodynamic study and the UDI-6 and IIQ-7 questionnaires.
Wróbel A; Skorupska K; Rechberger E; Woźniak A; Miotla P; Kubik-Komar A; Skorupski P; Rechberger T
Int Urogynecol J; 2019 Dec; 30(12):2135-2139. PubMed ID: 31396639
[TBL] [Abstract][Full Text] [Related]
24. Psychometric properties of the incontinence utility index among patients with idiopathic overactive bladder: data from two multicenter, double-blind, randomized, Phase 3, placebo-controlled clinical trials.
Castejón N; Khalaf K; Ni Q; Cuervo J; Patrick DL
Health Qual Life Outcomes; 2015 Aug; 13():116. PubMed ID: 26231052
[TBL] [Abstract][Full Text] [Related]
25. Impact of combined usage of questionnaire forms with bladder diary for overactive bladder syndrome.
Sonbahar AE; Durmaz K; Culha MG
Urologia; 2022 Nov; 89(4):517-520. PubMed ID: 35471101
[TBL] [Abstract][Full Text] [Related]
26. The translation and validation of Chinese overactive bladder symptom score for assessing overactive bladder syndrome and response to solifenacin treatment.
Chou EC; Hung MJ; Yen TW; Chuang YC; Meng E; Huang ST; Kuo HC
J Formos Med Assoc; 2014 Aug; 113(8):506-12. PubMed ID: 25037757
[TBL] [Abstract][Full Text] [Related]
27. Understanding the elements of overactive bladder: questions raised by the EPIC study.
Irwin DE; Abrams P; Milsom I; Kopp Z; Reilly K;
BJU Int; 2008 Jun; 101(11):1381-7. PubMed ID: 18336602
[TBL] [Abstract][Full Text] [Related]
28. Diary and patient-reported outcomes in patients with severe overactive bladder switching from tolterodine extended release 4 mg/day to solifenacin treatment: An open-label, flexible-dosing, multicentre study.
Swift SE; Siami P; Forero-Schwanhaeuser S
Clin Drug Investig; 2009; 29(5):305-16. PubMed ID: 19366272
[TBL] [Abstract][Full Text] [Related]
29. The impact of overactive bladder on mental health, work productivity and health-related quality of life in the UK and Sweden: results from EpiLUTS.
Coyne KS; Sexton CC; Kopp ZS; Ebel-Bitoun C; Milsom I; Chapple C
BJU Int; 2011 Nov; 108(9):1459-71. PubMed ID: 21371240
[TBL] [Abstract][Full Text] [Related]
30. Psychometric performance of the incontinence quality-of-life questionnaire among patients with overactive bladder and urinary incontinence.
Patrick DL; Khalaf KM; Dmochowski R; Kowalski JW; Globe DR
Clin Ther; 2013 Jun; 35(6):836-45. PubMed ID: 23747076
[TBL] [Abstract][Full Text] [Related]
31. [Impact of urinary incontinence and overactive bladder syndrome on health-related quality of life of working middle-aged patients and institutionalized elderly patients].
Martínez Agulló E; Ruíz Cerdá JL; Gómez Pérez L; Rebollo P; Pérez M; Chaves J
Actas Urol Esp; 2010 Mar; 34(3):242-50. PubMed ID: 20416241
[TBL] [Abstract][Full Text] [Related]
32. Sleep Disturbance and Fatigue Are Associated With More Severe Urinary Incontinence and Overactive Bladder Symptoms.
Ge TJ; Vetter J; Lai HH
Urology; 2017 Nov; 109():67-73. PubMed ID: 28826875
[TBL] [Abstract][Full Text] [Related]
33. Combined Tolterodine and Vaginal Estradiol Cream for Overactive Bladder Symptoms After Randomized Single-Therapy Treatment.
Ellington DR; Szychowski JM; Malek JM; Gerten KA; Burgio KL; Richter HE
Female Pelvic Med Reconstr Surg; 2016; 22(4):254-60. PubMed ID: 26945271
[TBL] [Abstract][Full Text] [Related]
34. [Validation of the International Consultation on Incontinence Questionnaire Overactive Bladder (ICIQ-OAB) for Portuguese].
Pereira SB; Thiel Rdo R; Riccetto C; Silva JM; Pereira LC; Herrmann V; Palma P
Rev Bras Ginecol Obstet; 2010 Jun; 32(6):273-8. PubMed ID: 20945012
[TBL] [Abstract][Full Text] [Related]
35. Evaluation of overactive bladder and nocturia as a risk factor for hip fracture in climacteric women: a matched pair case control study.
Karabulut A; Simavlı S; Demirtaş Ö; Ök N; Güngör HR; Zümrütbaş A
J Obstet Gynaecol; 2018 Feb; 38(2):252-256. PubMed ID: 28903631
[TBL] [Abstract][Full Text] [Related]
36. Impact of overactive bladder on quality of life and resource use: results from Korean Burden of Incontinence Study (KOBIS).
Lee KS; Choo MS; Seo JT; Oh SJ; Kim HG; Ng K; Lee KJ; Tan JT; Kim JC
Health Qual Life Outcomes; 2015 Jun; 13():89. PubMed ID: 26113125
[TBL] [Abstract][Full Text] [Related]
37. Establishing the content validity of the King's Health Questionnaire in men and women with overactive bladder in the US.
Margolis MK; Vats V; Coyne KS; Kelleher C
Patient; 2011; 4(3):177-87. PubMed ID: 21766913
[TBL] [Abstract][Full Text] [Related]
38. Urogynecological survey in a group of Italian women treated for overactive bladder: Symptoms and quality of life analysis during the Covid-19 period.
Schiavi MC; Zullo MA; Luffarelli P; Di Pinto A; Oliva C; Palazzetti P
Taiwan J Obstet Gynecol; 2021 Jul; 60(4):674-678. PubMed ID: 34247805
[TBL] [Abstract][Full Text] [Related]
39. The International Female Coital Incontinence Questionnaire (IFCI-Q): Development, Validation and Reliability Study.
Gubbiotti M; Giannantoni A; Rubilotta E; Balzarro M; Bini V; Rosadi S; Serati M
J Sex Med; 2022 Jan; 19(1):158-163. PubMed ID: 34876388
[TBL] [Abstract][Full Text] [Related]
40. Patient-reported outcomes in patients with overactive bladder treated with mirabegron and tolterodine in a prospective, double-blind, randomized, two-period crossover, multicenter study (PREFER).
Herschorn S; Staskin D; Tu LM; Fialkov J; Walsh T; Gooch K; Schermer CR
Health Qual Life Outcomes; 2018 Apr; 16(1):69. PubMed ID: 29673355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
